Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1776-1780

  Boileau, Isabelle ^a   Warsh, Jerry J ^a   Guttman, Mark ^a,b   Saint Cyr, Jean A ^a   McCluskey, Tina ^a   Rusjan, Pablo ^a   Houle, Sylvain ^a   Wilson, Alan A ^a   Meyer, Jeffrey H ^a   Kish, Stephen J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Centre for Movement Disorders   (Canada)

Author keywords

11C DASB; Depression; Parkinson's disease; Positron emission tomography; Serotonin transporter

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE C 11; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING SITE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; UPREGULATION;

AGED; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STATISTICS, NONPARAMETRIC; SULFIDES;

EID: 57049114907     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22212     Document Type: Article

References (21)

1. Poewe W, Luginger E. Depression in Parkinson's disease: impediments to recognition and treatment options. Neurology 1999; 52(7 Suppl 3):S2-S6.
2. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 200;15:1112-1118.
3. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 2003;91:39-49.
4. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008;28:441-444.
5. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007;14:523-528.
6. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003;60:1223-1229.
7. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
8. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 2001;27:1719-1722.
9. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threkleld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio) araalkylamines. J Med Chem 2000;43:3103-3110.
10. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001;21:1342-1353.
11. Rusjan PM, Mamo D, Ginovart N, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006;147:79-89.
12. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 2000;12:571-583.
13. Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
14. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86-102.
15. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-1078.
16. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007;62:870-877.
17. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004; 61:1271-1279.
18. Parsey RV, Hastings RS, Oquendo MA, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006;163:52-58.
19. Meyer JH. Applying neuroimaging ligands to study major depressive disorders. Semin Nucl Med 2008;38:287-304.
20. Talbot PS, Frankle WG, Hwang DR, et al. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse 2005; 55:164-175.
21. Praschak-Rieder N, Wilson AA, Hussey D, et al. Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry 2005;58:825-830.